Inclusion Criteria:

- Patients with histologically or cytologically confirmed locally advanced or
metastatic solid tumors or non-Hodgkin's lymphomas for which YM155 has the potential,
based on preclinical and/or clinical data, to show efficacy, namely:

- castrate resistant prostate cancer

- non-small cell lung cancer

- metastatic melanoma

- muscle invasive bladder cancer

- follicular lymphoma

- diffuse large B-cell lymphoma

- Life expectancy ≥ 3 months; and Performance status (PS) ≤ 2 on the Eastern
Cooperative Oncology Group (ECOG) scale at baseline

Exclusion Criteria:

- Radiotherapy, major surgery, hormonal therapy, and chemotherapy within 4 weeks prior
to the first dose of study medication and 6 weeks in the case of mitomycin-C or
nitrosourea

- Previous therapy with YM155

- Patients with renal, hepatic or colorectal cancers

- Inadequate bone marrow, renal and/or hepatic function

- History of being treated for other malignancy within 5 years except for treated basal
or squamous cell carcinoma of the skin

- Participation in any clinical study within 4 weeks prior to start of the first dose
of study medication

- Known brain or leptomeningeal metastases

- Active uncontrolled systemic infection at baseline